Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986416 +/- Nivolumab in Advanced Solid Tumors
NCT04943900Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Aug 2021
- Primary completion
- Feb 2025
- Modality
- Fc-Fusion Proteins
- Countries
- 7
01
Overview
Phase 1, open-label trial of BMS-986416 in solid tumor (advanced stage), non-small cell lung cancer (NSCLC), urothelial carcinoma (UC) and 4 more (2 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Incidence of Adverse Events up to 100 days, Incidence of Serious Adverse Events up to 100 days and 4 more. Started Aug 2021; status: completed.
02
Drugs
BMS-986416
03
Conditions
solid tumor (advanced stage)non-small cell lung cancer (NSCLC)urothelial carcinoma (UC)squamous cell carcinoma of the head and neck (HNSCC)hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04943900.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04943900.